Clinical Trial Update: A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating subcutaneous efgartigimod PH20 SC in adults with pemphigus vulgaris or foliaceus has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pemphigus Foliaceus
• Pemphigus Vulgaris

Drugs mentioned

• Efgartigimod (efgartigimod)

Snippet

Sponsor: argenx | Conditions: Pemphigus Vulgaris, Pemphigus Foliaceus | Phase 3 | Status: COMPLETED | Results posted: 2024-10-01